## NCCN Thyroid Carcinoma Guidelines V.1.2013 – Follow-up– 12/14/12

<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion</th>
<th>References</th>
<th>Vote</th>
</tr>
</thead>
</table>
| **Medullary Thyroid Carcinoma**  
*MEDU*-6 | Based on the recent FDA approval and supporting data in the noted references, the panel consensus was to add cabozantinib (category 1) as an option for the treatment of progressive, metastatic medullary thyroid cancer. | 1. Schoffski P, Elisei R, Muller S, et al. An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline [abstract]. J Clin Oncol 2012;30(Suppl 15): Abstract 5508.  
2. FDA Press Release [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm330213.htm](http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm330213.htm)  
3. Prescribing Information: [http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203756lbl.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203756lbl.pdf) | YES 16  
NO 2  
ABSTAIN 1 |
| **Anaplastic Thyroid Carcinoma**  
*ANAP-A* | Based on the recent publication of the American Thyroid Association Guidelines and the noted references, the following systemic therapy options were added for the treatment of anaplastic thyroid carcinoma:  
**Concurrent Chemoradiation Regimens**  
- Paclitaxel/Carboplatin  
- Paclitaxel  
- Cisplatin  
- Doxorubicin  
**Chemotherapy Regimens**  
- Paclitaxel/Carboplatin  
- Paclitaxel  
NO 0  
ABSTAIN 2 |